Forget Biotech's Binary Bets: This Dividend Stock Collects Royalties on Blockbusters Instead

Royalty Pharma (RPRX) offers a lower-risk alternative to traditional biotech investing by collecting royalties on a diversified portfolio of 35 approved drugs and 16 drugs in development, including 16 blockbuster drugs generating over $1 billion in sales. The company's professional management team has demonstrated strong track record with 14 drugs outperforming original sales expectations, while providing steady dividend growth since going public in 2020.